MeSH term
Frequency | Condition_Probility | Humans | 179 | 0.0 |
Seasons | 2 | 1.0 |
Blood Glucose/analysis | 5 | 0.0 |
Child | 11 | 0.0 |
Fasting | 3 | 0.0 |
Female | 75 | 0.0 |
Glucose Tolerance Test | 10 | 2.0 |
Linear Models | 3 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
Male | 82 | 0.0 |
Models, Biological | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 87 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 40 | 0.0 |
Blood Glucose/metabolism | 6 | 0.0 |
Body Mass Index | 6 | 0.0 |
Middle Aged | 50 | 0.0 |
Infant | 9 | 0.0 |
Animals | 25 | 0.0 |
Mice | 5 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Adult | 70 | 0.0 |
Attention/*physiology | 2 | 4.0 |
Brain Mapping | 4 | 2.0 |
Evoked Potentials, Somatosensory/physiology | 2 | 15.0 |
Laterality/physiology | 3 | 5.0 |
*Magnetic Resonance Imaging | 4 | 2.0 |
Somatosensory Cortex/*physiology | 3 | 15.0 |
Touch/*physiology | 3 | 33.0 |
Brain/*physiology | 2 | 1.0 |
Comparative Study | 32 | 0.0 |
Heat | 5 | 0.0 |
Magnetic Resonance Imaging | 8 | 0.0 |
Neural Pathways/physiology | 2 | 6.0 |
Pain/*physiopathology | 3 | 10.0 |
Prospective Studies | 10 | 0.0 |
CD4 Lymphocyte Count | 6 | 0.0 |
HIV Envelope Protein gp120/*genetics | 2 | 8.0 |
HIV-1/*genetics | 2 | 0.0 |
Molecular Sequence Data | 15 | 0.0 |
Homeostasis | 2 | 0.0 |
Insulin/blood | 6 | 0.0 |
*Insulin Resistance | 8 | 4.0 |
Logistic Models | 2 | 0.0 |
Proinsulin/*blood | 4 | 36.0 |
Magnetoencephalography | 3 | 42.0 |
Physical Stimulation | 3 | 6.0 |
Somatosensory Cortex/anatomy & histology/*physiology | 3 | 100.0 |
Analysis of Variance | 4 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 12 | 0.0 |
Swine/*genetics | 2 | 1.0 |
Reference Values | 11 | 0.0 |
Computer Simulation | 2 | 0.0 |
Phenotype | 21 | 0.0 |
Base Sequence | 6 | 0.0 |
Caco-2 Cells | 5 | 1.0 |
Gene Expression Regulation, Enzymologic | 4 | 0.0 |
Glycosylceramidase/genetics/metabolism | 2 | 100.0 |
*Nuclear Proteins | 3 | 0.0 |
Sucrase-Isomaltase Complex/genetics/metabolism | 3 | 50.0 |
Transfection | 2 | 0.0 |
Cell Differentiation | 4 | 0.0 |
DNA Primers | 3 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Sucrase-Isomaltase Complex/*genetics | 6 | 85.0 |
*Transcription, Genetic | 3 | 0.0 |
Adolescent | 15 | 0.0 |
Cell Line | 18 | 0.0 |
Hamsters | 2 | 0.0 |
RNA, Viral/genetics/*metabolism | 2 | 16.0 |
C-Peptide/blood | 2 | 1.0 |
Case-Control Studies | 2 | 0.0 |
Insulin/blood/secretion | 3 | 14.0 |
Aged | 30 | 0.0 |
Aged, 80 and over | 11 | 0.0 |
Disease Progression | 5 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Sensitivity and Specificity | 6 | 0.0 |
Brain Mapping/*methods | 2 | 8.0 |
Oxygen/blood | 3 | 2.0 |
Blood Pressure | 3 | 0.0 |
Triglycerides/blood | 2 | 0.0 |
Amino Acid Sequence | 10 | 0.0 |
Giant Cells/*virology | 3 | 30.0 |
HIV Envelope Protein gp120/genetics | 2 | 5.0 |
HIV Infections/*virology | 2 | 2.0 |
Peptide Fragments/genetics | 2 | 2.0 |
Phylogeny | 3 | 0.0 |
Receptors, CCR5/genetics | 2 | 3.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Cells, Cultured | 8 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Kinetics | 5 | 0.0 |
Viral Load | 3 | 0.0 |
Anti-HIV Agents/*therapeutic use | 3 | 0.0 |
Didanosine/therapeutic use | 2 | 4.0 |
Double-Blind Method | 4 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Giant Cells/virology | 6 | 15.0 |
RNA, Viral/blood | 4 | 0.0 |
Zidovudine/therapeutic use | 2 | 1.0 |
English Abstract | 10 | 0.0 |
Iron/*blood | 2 | 5.0 |
Pregnancy | 5 | 0.0 |
Biological Transport | 4 | 0.0 |
Biopsy | 5 | 0.0 |
Child, Preschool | 8 | 0.0 |
Golgi Apparatus/metabolism | 2 | 1.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Models, Molecular | 2 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
HIV Antibodies/blood | 2 | 2.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Photons | 2 | 15.0 |
Cross-Sectional Studies | 3 | 0.0 |
Sex Factors | 3 | 0.0 |
Ferritin/blood | 3 | 1.0 |
Phosphorylation | 3 | 0.0 |
Signal Transduction | 2 | 0.0 |
*Models, Biological | 2 | 1.0 |
Reproducibility of Results | 2 | 0.0 |
CD4-Positive T-Lymphocytes/*virology | 2 | 2.0 |
Genotype | 5 | 0.0 |
Virus Replication | 2 | 0.0 |
*Brain Mapping | 2 | 4.0 |
Face/physiology | 2 | 100.0 |
Reaction Time | 2 | 1.0 |
Methods | 2 | 0.0 |
Area Under Curve | 2 | 0.0 |
Time Factors | 12 | 0.0 |
*Protein Processing, Post-Translational | 2 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Follow-Up Studies | 7 | 0.0 |
Immunity, Cellular | 2 | 0.0 |
Neutralization Tests | 2 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Clone Cells | 3 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
Microvilli/enzymology | 6 | 28.0 |
Chronic Disease | 4 | 0.0 |
Evaluation Studies | 3 | 0.0 |
Age Factors | 3 | 0.0 |
Insulin Resistance | 2 | 1.0 |
*Variation (Genetics) | 2 | 0.0 |
Diagnosis, Differential | 5 | 0.0 |
Kidney Glomerulus/*metabolism | 2 | 6.0 |
Binding Sites | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Glucose/*pharmacology | 2 | 2.0 |
HIV Core Protein p24/blood | 2 | 2.0 |
RNA, Viral/*blood | 2 | 1.0 |
Zidovudine/*therapeutic use | 2 | 1.0 |
Coculture Techniques | 2 | 0.0 |
Staining and Labeling | 3 | 0.0 |
In Vitro | 2 | 0.0 |
Iron/chemistry | 2 | 13.0 |
Cohort Studies | 3 | 0.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
Rats | 5 | 0.0 |
Sucrase-Isomaltase Complex/*metabolism | 5 | 83.0 |
Aminopeptidases/metabolism | 2 | 40.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Lactase | 2 | 40.0 |
Sucrase-Isomaltase Complex/*biosynthesis | 3 | 100.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
In Situ Hybridization | 2 | 0.0 |
Cross Reactions | 2 | 0.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
Serotyping | 2 | 0.0 |
Aluminum/blood | 2 | 33.0 |
Renal Dialysis/*adverse effects | 2 | 1.0 |
Spectrophotometry, Atomic | 3 | 6.0 |
Silicon/*analysis | 2 | 100.0 |
Infant, Newborn | 5 | 0.0 |
Leukocytes, Mononuclear/virology | 2 | 1.0 |
Retrospective Studies | 6 | 0.0 |
Glucose/metabolism | 4 | 1.0 |
Blood Glucose/*metabolism | 2 | 0.0 |
HIV-1/*immunology | 3 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Prognosis | 4 | 0.0 |
Sucrase-Isomaltase Complex/*analysis | 4 | 100.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Transcription, Genetic | 4 | 0.0 |
Leukocyte Count | 3 | 0.0 |
Giant Cells | 2 | 3.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Homeodomain Proteins/*metabolism | 2 | 1.0 |
Colorectal Neoplasms/*enzymology/ultrastructure | 2 | 100.0 |
Survival Rate | 2 | 0.0 |
Risk Factors | 5 | 0.0 |
*Gene Expression Regulation | 2 | 0.0 |
Epithelium/enzymology | 2 | 5.0 |
Intestines/*enzymology | 2 | 5.0 |
Multivariate Analysis | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Electromagnetic Fields | 2 | 13.0 |
*Magnetoencephalography | 2 | 25.0 |
Statistics | 2 | 0.0 |
*Chromosomes, Human, Pair 3 | 3 | 0.0 |
Evoked Potentials | 2 | 3.0 |
Drug Combinations | 2 | 0.0 |
Copper/chemistry | 2 | 10.0 |
Fluorides/chemistry/*radiation effects | 2 | 66.0 |
Lithium Compounds/chemistry/*radiation effects | 2 | 50.0 |
Luminescent Measurements | 2 | 2.0 |
Magnesium/chemistry | 2 | 10.0 |
Radiochemistry | 2 | 18.0 |
Silicon/chemistry | 2 | 66.0 |
Sodium/chemistry | 2 | 40.0 |
*Glucose Tolerance Test | 2 | 3.0 |
Species Specificity | 3 | 0.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
*Lymphocyte Activation | 2 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Antigens, CD13 | 2 | 3.0 |
Methionine/metabolism | 2 | 1.0 |
Microvilli/*enzymology | 2 | 50.0 |
Protein Transport | 2 | 0.0 |
Mice, Inbred ICR | 2 | 0.0 |
Molecular Weight | 4 | 0.0 |
Intestinal Mucosa/enzymology | 2 | 6.0 |
Hematocrit | 2 | 0.0 |
Hemoglobins/analysis | 2 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Electric Stimulation | 2 | 0.0 |
Acute Disease | 3 | 0.0 |
Multienzyme Complexes/*analysis | 2 | 33.0 |
Organ Culture Techniques | 2 | 0.0 |
Intestinal Mucosa/*enzymology | 2 | 10.0 |
Peptide Fragments/analysis | 2 | 0.0 |
Multienzyme Complexes/*genetics | 2 | 2.0 |
X-Rays | 2 | 1.0 |
Enzyme Activation | 2 | 0.0 |
